Clinical Trials Logo

Filter by:
NCT ID: NCT05909904 Recruiting - Clinical trials for Head and Neck Cancer

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Start date: July 21, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT05908812 Recruiting - Obesity Clinical Trials

Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity

Start date: February 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to compare glycemic control and irisin levels in subjects with diabetes mellitus type 2 with sarcopenic obesity vs non-sarcopenic obesity. The main questions it aims to answer are: Is glycemic control worse in diabetic patients with sarcopenic obesity? Are irisin levels higher in patients with non-sarcopenic obesity? Participants will be asked to: - Fill in three questionaries on lifestyle - Perform two physical performance tests The investigators will collect the following data: - Anthropometric measurements - Body composition by bioelectrical impedance analysis. - Results of routine blood analyses - Irisin levels by drawing a vial of blood from the antecubital vein

NCT ID: NCT05907954 Recruiting - Uveal Melanoma Clinical Trials

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Start date: July 3, 2023
Phase: Phase 2
Study type: Interventional

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

NCT ID: NCT05907655 Recruiting - Migraine Clinical Trials

Study of the Glymphatic System in Migraine

Start date: April 30, 2023
Phase:
Study type: Observational

This study aimed to investigate the role of the glymphatic system in the initiation of migraine attacks, using non-invasive magnetic resonance imaging techniques and a validated model of migraine induction by nitroglycerin administration. Secondarily, the relationship between the function of the glymphatic system during nitroglycerin-induced migraine attacks and sleep architecture and plasma levels of migraine-involved neuropeptides will be investigated.

NCT ID: NCT05907434 Recruiting - Acute Kidney Injury Clinical Trials

Cell Cycle Arrest Proteins for Early Diagnosis of Acute Kidney Injury After Lung Transplant

LUTX_AKI
Start date: February 1, 2022
Phase:
Study type: Observational

Renal failure is a common complication of lung transplant (LUTX). Early diagnosis of acute kidney injury (AKI) in this cohort is of utmost importance, since AKI after LUTX is associated with worsened short and long-term outcomes. To now, early biomarkers of renal failure based on the measurement of cell-cycle arrest proteins have never been tested in this population.

NCT ID: NCT05907291 Recruiting - Clinical trials for Congenital Adrenal Hyperplasia

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Start date: July 3, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of CRN04894 in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

NCT ID: NCT05907122 Recruiting - Melanoma Clinical Trials

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Start date: July 26, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.

NCT ID: NCT05907057 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Start date: June 14, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive [IDH1m]) and cannot receive treatment with intensive chemotherapy (IC).

NCT ID: NCT05906810 Recruiting - Atherosclerosis Clinical Trials

Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Peri-implantitis and Peri-implant Mucositis

Start date: October 5, 2020
Phase: N/A
Study type: Interventional

A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with peri-implantitis/peri-implant mucositis and without any cardiovascular disease.

NCT ID: NCT05906680 Recruiting - IBD Clinical Trials

The Gut Virome as a Trigger for IBD: From Metagenomics to Pathogenesis

Start date: February 7, 2023
Phase:
Study type: Observational

Alterations in the composition of the intestinal microbiota (dysbiosis) are well known involved in the pathogenesis of gastrointestinal disorders, such as inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD). While bacteria have always gotten the most attention in gastrointestinal disorders, the viral component of the human gut microbiome, called the "gut virome", is underestimated. In addition to bacteriophages, the gut virome also harbors viruses that infect eukaryotic cells, capable of transferring their information directly to host cells, and associated with the pathogenesis of both UC and CD. Although a substantial number of studies have described the viral composition of gut microbiota in human feces, it is necessary to define the entire eukaryotic virome which colonizes the intestinal mucosa of patients with inflammatory bowel disease and which intestinal cell population is most affected. Therefore, this study aims at a comprehensive metagenomic analysis on single cells of the intestinal mucosa from a large cohort of treatment-naïve young patients with IBD at their first diagnosis to find out which cells are affected by eukaryotic viruses in the early stages of the onset of IBD and how it can affect the immune response of the mucosa, eventually leading to chronic intestinal inflammation.